Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of amlodipine, losartan, and atenolol on cerebrovascular reactivity in symptomatic cerebral small vessel disease
NL-OMON53102Phase 3Active, not recruiting
- Sponsor
- LMU Klinikum
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amlodipine, losartan and atenolol in Cerebral Small Vessel Disease (CSVD) (3 arms), sponsored by LMU Klinikum. Primary endpoint: Cerebrovascular reactivity. Started Oct 2018; status: active, not recruiting.
02
Drugs
amlodipinelosartanatenolol
03
Conditions
Cerebral Small Vessel Disease (CSVD)
Beyond the preview
Go deeper on NL-OMON53102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53102.